文献速递甲状腺核医学核素与放射性配体治疗

分化型甲状腺癌患者的肽受体放射性核素治疗:一项Meta分析

Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis.
PubMed 文献 · Clin Nucl Med · 2020-01-01

该Meta分析纳入11篇文章共165例患者(甲状腺髓样癌98例、分化型非髓样甲状腺癌67例),评估肽受体放射性核素治疗(PRRT)的疗效与安全性。PRRT在甲状腺髓样癌和分化型非髓样甲状腺癌患者中汇总的客观缓解率为8.53%至15.61%,疾病控制率为53.95%至59.99%,严重不良事件(3级或4级)为2.79%至2.82%。基于镥的PRRT(客观缓解率11.48%至24.52%,疾病控制率61.47%至67.26%)显示出优于基于钇的PRRT(客观缓解率6.98%至13.82%,疾病控制率50.86%至57.29%)的治疗效果。

要点

  • PRRT在甲状腺髓样癌和分化型非髓样甲状腺癌中汇总的客观缓解率为8.53%至15.61%,疾病控制率为53.95%至59.99%。
  • PRRT严重不良事件(3级或4级)的汇总比例为2.79%至2.82%。
  • 基于镥的PRRT在客观缓解率和疾病控制率上均优于基于钇的PRRT。

核心结论

  • 该Meta分析提示,PRRT可能是甲状腺髓样癌和分化型非髓样甲状腺癌的一种有潜力且安全的治疗策略。
  • 作者认为,基于镥的PRRT相对于基于钇的PRRT表现出更好的治疗效果。

研究设计与样本

  • 系统检索PUBMED、EMBASE、CINAHL、SCOPUS和COCHRANE数据库的Meta分析。
  • 共纳入11篇文章、165例患者,其中甲状腺髓样癌98例,分化型非髓样甲状腺癌67例。
  • 主要疗效指标为PRRT后的影像学缓解,分别确定甲状腺髓样癌和分化型非髓样甲状腺癌的客观缓解率(ORR)和疾病控制率(DCR)。
  • 亚组分析评估严重不良事件(3级或4级)、F-FDG PET/CT和生化(降钙素和甲状腺球蛋白)反应的额外治疗效应以及PRRT所用放射性核素。
  • 参数以汇总比例生成。

主要发现

  • 在甲状腺髓样癌和分化型非髓样甲状腺癌患者中,PRRT汇总的客观缓解率为8.53%至15.61%,疾病控制率为53.95%至59.99%,严重不良事件为2.79%至2.82%。
  • F-FDG PET/CT和生化反应显示与影像学缓解相似的结果。
  • 基于镥的PRRT(客观缓解率11.48%至24.52%;疾病控制率61.47%至67.26%)显示出优于基于钇的PRRT(客观缓解率6.98%至13.82%;疾病控制率50.86%至57.29%)的治疗效果。

关键数值与推荐

  • PRRT在甲状腺髓样癌和分化型非髓样甲状腺癌患者中汇总的客观缓解率为8.53%至15.61%。
  • PRRT在甲状腺髓样癌和分化型非髓样甲状腺癌患者中汇总的疾病控制率为53.95%至59.99%。
  • PRRT在甲状腺髓样癌和分化型非髓样甲状腺癌患者中汇总的严重不良事件(3级或4级)比例为2.79%至2.82%。
  • 基于镥的PRRT的客观缓解率为11.48%至24.52%,疾病控制率为61.47%至67.26%。
  • 基于钇的PRRT的客观缓解率为6.98%至13.82%,疾病控制率为50.86%至57.29%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: As patients with progressive medullary thyroid cancer (MTC) and radioiodine-refractory metastatic differentiated nonmedullary thyroid cancer (DTC) have poor prognoses and present therapeutic challenges, peptide receptor radionuclide therapy (PRRT) targeting the somatostatin receptor provides a promising option. This meta-analysis evaluated the therapeutic effects and outcomes of PRRT in differentiated thyroid cancer. PATIENTS AND METHODS: PUBMED, EMBASE, CINAHL, SCOPUS, and COCHRANE were systematically searched using appropriate key words. The primary therapeutic effect was the radiological response after PRRT, and the objective response rate (ORR) and disease control rate (DCR) were identified in MTC and DTC, respectively. The outcome of serious adverse events (grade 3 or 4), additional therapeutic effects of F-FDG PET/CT and biochemical (calcitonin and thyroglobulin) responses, and radionuclides for PRRT were assessed as subgroup analyses. The parameters were generated as pooled proportions. RESULTS: Eleven articles with 165 patients were included (98 patients with MTC and 67 patients with DTC). PRRT achieved pooled proportions of ORR in 8.53% to 15.61%, DCR in 53.95% to 59.99%, and serious adverse events in 2.79% to 2.82% in MTC and DTC patients. F-FDG PET/CT and biochemical responses revealed similar results as the radiological response. Lu-based PRRT (ORR, 11.48%-24.52%; DCR, 61.47%-67.26%) showed better therapeutic effects than Y-based PRRT (ORR, 6.98%-13.82%; DCR, 50.86%-57.29%). CONCLUSIONS: This meta-analysis suggests that PRRT could be a potential and safe strategy for MTC and DTC. In particular, PRRT with Lu exhibited improved therapeutic effects relative to PRRT with Y.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lee DY, Kim YI. Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis. Clin Nucl Med. 2020. PMID: 32520503. doi:10.1097/RLU.0000000000003110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。